By Fineline Cube 
Shenzhen-based DNA sequencer specialist GeneMind Biosciences Co., Ltd. has reportedly secured RMB 280 million (USD 38.9 million) in a Series C+ financing round. The round was led by Sansure Biotech Inc. (SHA: 688289), Kingmed Diagnostics (SHA: 603882), Shengwei Rongquan Venture Capital, and Kinghall Ventures, with participation from Voyagers Capital, Haikou Junxin, Probitas Capital, and others.
Funding to Accelerate Innovation and Expansion
The proceeds from the financing will be allocated to further advance GeneMind’s technological leadership in the DNA sequencing space. Since its Series C financing in August 2023, the company has launched two flagship products: the SURFSeq 5000, the world’s highest-throughput desktop gene sequencer with a capacity of 2.2Tb per run, and the SURFSeq Q, the world’s highest daily-output ultra-high-throughput sequencer, capable of delivering 9Tb per day. These innovations highlight GeneMind’s commitment to pushing the boundaries of genetic sequencing technology.
Regulatory Approvals and Market Entry
GeneMind has achieved significant regulatory milestones with two of its products being approved as Class III medical devices by China’s National Medical Products Administration (NMPA). The GenoLab M Dx, approved in September 2024, stands as the first domestically produced high-throughput gene sequencer in China to employ the reversible termination sequencing method. Additionally, the FASTASeq 300 Dx, approved in April 2025, offers clinical advantages in speed, cost, and sample flexibility, further solidifying GeneMind’s position in the diagnostic landscape.-Fineline Info & Tech